European Commission Approves Astellas’ XospataAccelerated Assessment, Acute Myeloid Leukemia (AML), Approvals, Central Europe, EU, European Commission, FDA/Regulatory, FLT3 Mutations, Iceland, Liechtenstein, NorwayThe European Commission approved Astellas Pharma’s oral once-daily therapy Xospata as a monotherapy for treating adults with relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Read more October 25, 2019/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2019-10-25 03:00:362019-10-25 13:27:14European Commission Approves Astellas’ Xospata